Lotus Pharmaceuticals (1795:TW)

Executive Summary

Lotus Pharmaceuticals is a Taiwan-based publicly traded specialty pharmaceutical company (stock code 1795 TT) that develops, manufactures, and commercializes a diversified portfolio of generic and biosimilar medicines with a strong emphasis on oncology and immunology. Founded in 2020 and employing over 1,000 people, the company leverages a hybrid model combining in-house R&D and strategic partnerships to deliver complex generics, 505(b)(2) products, and novel compounds across more than 90 markets worldwide. Its focus on high-barrier-to-entry therapeutic areas positions it well in the growing global demand for affordable biologics and specialty generics. Financially, Lotus has established a robust commercial presence and benefits from its inclusion in the Taiwan Stock Exchange. The company’s strategy of expanding its oncology pipeline through in-licensing and internal development, coupled with a broad geographic reach, supports sustainable growth. Key upcoming catalysts include potential FDA approval for a high-value generic oncology product, a strategic partnership for biosimilar development, and positive late-stage clinical readouts for a 505(b)(2) asset. These events could significantly enhance revenue streams and consolidate Lotus's position in the specialty pharma landscape.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of generic oncology injectable70% success
• Q1 2027Licensing or partnership agreement for a biosimilar candidate60% success
• TBDPositive Phase 3 results for a 505(b)(2) immunology product50% success